Landmark trial
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
Brunt AM, Haviland JS, Wheatley DA, et al.
DoseLab summary
Five-year results of the UK FAST-Forward trial, comparing one week of whole-breast or chest wall radiotherapy with three weeks. Citation as given in the eviQ reference list; not yet checked against the journal.
Why this is useful
The trial behind 26 Gy in 5 fractions — and the source of the 5-fraction lung and heart limits in DoseLab's breast tables.
Reference details
- Title
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
- Authors / organization
- Brunt AM, Haviland JS, Wheatley DA, et al.
- Publication / protocol
- Lancet. 2020;395(10237):1613–1626
- Version
- Pending verification
- Year
- 2020
- DOI
- Pending verification
- Disease sites
- Breast
- Topics
- Breast, Hypofractionation, Landmark trial, Dose Constraints
- Fractionation context
- 26 Gy/5 fx vs 40 Gy/15 fx
- Last reviewed by DoseLab
- Pending verification